The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth
Myeloid Derived Suppressor Cells (MDSC) represent a significant hurdle to cancer immunotherapy because they dampen anti-tumor cytotoxic T cell responses. Previous studies have reported on the myelo-depletive effects of certain chemotherapies. Using guadecitabine, a next-generation DNA methyltransfer...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2019
|
| Subjects: | |
| Online Access: | https://scholarscompass.vcu.edu/etd/5792 https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=6880&context=etd |